- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01052285
The Efficacy of Transversus Abdominis Plane Block After Groin Hernia Repair
November 17, 2011 updated by: Pernille Lykke Petersen, Glostrup University Hospital, Copenhagen
The Efficacy of Transversus Abdominis Plane Block Versus Placebo Versus Local Infiltration in Patients Undergoing Groin Hernia Repair in Day Case Surgery.
The purpose of this study is to determine whether Transversus abdominis plane block is superior to placebo or superior to local infiltration in analgesic efficacy after groin hernia repair.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
90
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Glostrup, Denmark, 2600
- Department of Anaesthesiology, Glostrup University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18-75 years old
- groin hernia repair
- written consent
- ASA 1-3
- BMI 18-35
Exclusion Criteria:
- unable to communicate in Danish
- relevant drug allergy
- pain medication in the last 24 hours
- pregnancy
- alcohol or/and drug abuse
- daily opioid intake
- infection at injection site
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
TAP block with 25 ml of saline Ilioinguinal block with 10 ml of saline and local infiltration with 40 ml of saline.
|
UL-guided Tap block with 25 ml of saline single dose Ilioinguinal block with 10 ml of saline and local infiltration with saline 40 ml single dose
Other Names:
|
|
Active Comparator: Local infiltration
Ilioinguinal block with 10 ml of ropivacaine 0,375% Local infiltration with 40 ml of ropivacaine 0,375% Tap block with 25 ml of saline
|
Ilioinguinal block with 10 ml of ropivacaine 0,375% single dose, local infiltration with 40 ml of ropivacaine 0,375% single dose, UL-guided Tap block with 25 ml of saline single dose
Other Names:
|
|
Experimental: Transversus abdominis plane block
25 ml of Ropivacaine 0,75%, Ilioinguinal block with 10 ml saline and local infiltration with 40 ml of saline.
|
UL-guided TAP block with 25 ml of ropivacaine 0,75% unilateral, single dose, ilioinguinal block with 10 ml of saline and local infiltration with 40 ml of saline
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain scores by coughing between TAP block group and placebo group
Time Frame: 0,2,4,6,8,19 and 24 hours postoperative
|
Area under the curve (AUC)-pain during cough based on measurements at 0,2,4,6,8,19,24 hours postoperative
|
0,2,4,6,8,19 and 24 hours postoperative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain scores by coughing between placebo and local infiltration and between TAP block and local infiltration.
Time Frame: 0,2,4,6,8,19 and 24 hours postoperative
|
Area under the curve (AUC)-pain during cough based on measurements 0,2,4,6,8,19,24 hours postoperative.
|
0,2,4,6,8,19 and 24 hours postoperative
|
|
Total opioid consumption
Time Frame: 0-24 hours postoperative
|
Total morphine consumption 0-2 hours postoperative.
Total ketobemidone consumption 2-24 hours postoperative.
|
0-24 hours postoperative
|
|
Postoperative nausea and vomiting
Time Frame: 0,2,4,6,8,19,24 hours postoperative
|
Levels of nausea (0-3)at 0,2,4,6,8,19,24 hours postoperative Number of vomits 0-2, 2-4, 4-6, 6-8, 8-19 og 19-24 hours postoperative.
|
0,2,4,6,8,19,24 hours postoperative
|
|
Sedation
Time Frame: 0,2,4,6,8,19,24 hours postoperative
|
Levels of sedation (0-3)at 0,2,4,6,8,19,24 hours postoperative.
|
0,2,4,6,8,19,24 hours postoperative
|
|
Pain scores at rest between TAP block versus placebo and TAP block versus infiltration and infiltration versus placebo
Time Frame: 0,2,4,6,8,19,24 hours postoperative
|
Area under the curve (AUC)-pain at rest based on measurements at 0,2,4,6,8,19,24 hours postoperative
|
0,2,4,6,8,19,24 hours postoperative
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Pernille L Petersen, MD, Glostrup University Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2010
Primary Completion (Actual)
November 1, 2011
Study Completion (Actual)
November 1, 2011
Study Registration Dates
First Submitted
January 19, 2010
First Submitted That Met QC Criteria
January 19, 2010
First Posted (Estimate)
January 20, 2010
Study Record Updates
Last Update Posted (Estimate)
November 18, 2011
Last Update Submitted That Met QC Criteria
November 17, 2011
Last Verified
November 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SM1-plp-10
- 2010-018403-29 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hernia
-
Muhammet Mustafa VuralRecruitingInguinal Hernia | Femoral Hernia | Obturator HerniaTurkey
-
University of California, DavisNot yet recruitingInguinal Hernia | Hernia | Hiatal Hernia | Ventral Hernia | Diastasis Recti | Hernia Abdominal WallUnited States
-
University of NebraskaLifeCellCompletedHiatal Hernia | Esophageal Hernia | Hernia, Esophageal | Hernia, Paraesophageal | Paraesophageal Hiatal Hernia | Sliding Esophageal Hernia | Sliding Hiatal HerniaUnited States
-
Mette Astrup MadsenCompletedInguinal Hernia | Femoral HerniaDenmark
-
Medtronic - MITGCompletedInguinal Hernia | Ventral HerniaUnited States
-
Advanced Medical Solutions Ltd.CompletedInguinal Hernia | Hernia | Femoral Hernia | Groin HerniaUnited States
-
The Cleveland ClinicJoseph and Florence Mandel Family FoundationRecruitingHernia | Hernia Surgery | Hernia Incisional | Hernia Incisional Ventral | Hernia Abdominal Wall | Hernia Repair With Compartment Syndrome | Botox InjectionUnited States
-
Hobart HarrisWithdrawnHernia | Ventral Hernia | Abdominal Hernia
-
GSVM Medical CollegeCompleted
-
Konya Meram State HospitalCompletedInguinal Hernia | Ventral Hernia | General SurgeryTurkey
Clinical Trials on Saline
-
Johns Hopkins UniversityCystic Fibrosis FoundationCompletedCystic Fibrosis
-
Children's Hospital Los AngelesThrasher Research Fund; UCSF Benioff Children's Hospital OaklandCompleted
-
University Hospital Inselspital, BerneCompletedCardiovascular Diseases | Valvular Heart DiseaseSwitzerland
-
Imam Abdulrahman Bin Faisal UniversityUnknownOtorhinolaryngologic Diseases | RhinosinusitisSaudi Arabia
-
Qassim UniversityCompletedApical Periodontitis | Post Operative Pain | Dental Pulp NecrosesSaudi Arabia
-
Aalborg UniversityThe Danish Rheumatism AssociationCompleted
-
Dr. Michael FlavinWithdrawn
-
CF Therapeutics Development Network Coordinating...National Heart, Lung, and Blood Institute (NHLBI); Cystic Fibrosis FoundationCompleted
-
Szpital im. Św. Jadwigi ŚląskiejCompleted
-
Makassed General HospitalCompletedLength of Hospital StayLebanon